Natera, Inc. and Kupando Therapeutics Launch Phase 1 Study to Monitor ctDNA in Advanced Skin Cancers
AUSTIN, Texas, August 12, 2026 Natera, Inc. announced a new collaboration with Kupando Therapeutics to support a Phase 1...
ctDNA
Advertisement
Natera Reports Signatera Superior to AMERK in MCC Monitoring
AUSTIN, Texas, July 22, 2026 Natera announced the publication of a prospective, multicenter study in JAMA Dermatology demonstrating that...
City of Hope Launches Phase 2 Lung Cancer Biomarker Trial
LOS ANGELES, July 21, 2026 City of Hope has launched the national Phase 2 IMMUNO-BIOMAP clinical trial to better...
Haier Biomedical Unveils Digital Blood Management Platform
KUALA LUMPUR, Malaysia, July 21, 2026 Haier Biomedical showcased its next-generation Digital Blood Management Platform at the ISBT Congress...
Tempus to Acquire Personalis in $1.5B Precision Oncology Deal
CHICAGO, July 20, 2026 Tempus AI, Inc. has entered into a definitive agreement to acquire Personalis, Inc. in a...
Advertisements
Quest Diagnostics Secures New York Approval for Haystack MRD Cancer Test
SECAUCUS, N.J., June 24, 2026 Quest Diagnostics announced that the New York State Department of Health’s Clinical Laboratory Evaluation...
AstraZeneca’s Camizestrant Extends Survival in ESR1-Mutant Breast Cancer
CHICAGO, Illinois, USA, June 2, 2026 AstraZeneca has announced compelling new results from its pivotal Phase III SERENA-6 trial,...
Natera Partners with Diakonos Oncology to Evaluate Signatera in Refractory Melanoma Trial
AUSTIN, Texas | May 2026 Natera, Inc. announced a new collaboration with Diakonos Oncology Corp. to utilize its personalized...
Hansa Biopharma Reports Positive Idefirix Results
LUND, Sweden, May 27, 2026 Hansa Biopharma AB has announced positive topline results from its European Post Authorization Efficacy...
TransCode Starts Phase 2a Trial for TTX-MC138
BOSTON, May 27, 2026 TransCode Therapeutics, Inc., a clinical-stage biotechnology company focused on RNA-based cancer therapeutics, has announced the...
Advertisement
